DMS53（人小細(xì)胞肺癌細(xì)胞）
CBP60172
詢(xún) 價(jià)
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
| I. General information | |
| Synonyms: | DMS53 |
| Background: | The line was established from cells from a mediastinal biopsy of a patient with small cell carcinoma of the lung. The patient had not received prior therapy. |
| Species: | Homo sapiens, human |
| Tissue: | lung |
| Disease: | carcinoma; small cell lung cancer |
| Gender: | male,54 years,Caucasian |
| Morphology: | epithelial |
| Growth Mode: | adherent |
| DNA Profile: | Amelogenin: X CSF1PO: 12 D13S317: 10 D16S539: 12,13 D5S818: 10,11 D7S820: 8,11 THO1: 8,9.3 TPOX: 12 vWA: 15,17 Our Cell Line Authentication Service |
| Culture Medium: |
RPMI-1640+10%FBS DMS53完全培養(yǎng)基，# CBP60172M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Antigen Expression: | Leu 7; My23 |
| Receptor Expression: | bombesin, expressed.epidermal growth factor (EGF), expressed transforming growth factor beta (TGF beta), expressed,acetylcholine, expressed |
| Genes Expressed: | adrenocorticotropin (adrenocorticotropic hormone, ACTH); bombesin; calcitonin; human chorionic gonadotropin (hCG); glucagon; growth hormone; 17 beta estradiol; thyroid releasing hormone; oxytocin - neurophysin (OT-NP); parathormone;,somatostatin-like immunoreactivity (SRIF) |
| Cellular Products: | adrenocorticotropin (adrenocorticotropic hormone, ACTH); bombesin; calcitonin; human chorionic gonadotropin (hCG); glucagon; growth hormone; 17 beta estradiol; thyroid releasing hormone; oxytocin - neurophysin (OT-NP); parathormone; somatostatin-like immunoreactivity (SRIF) |
| Tumor Formation: | Yes, tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 107 cells. |
| Comments: | The patient had not received prior therapy. The cells express HLA class I and class II antigens. Early passages of the cells were contaminated with a bovine mycoplasma (Acholeplasma laidlawii) which was cured (prior to cryopreservation) with A. laidlawii antiserum and kanamycin derived products. For more information, please contact us (4008-750-250). |
